TrialPloS one2013

Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer.

Salvatore Siena et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.